Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LAM Pilot Study With Imatinib Mesylate

Trial Profile

LAM Pilot Study With Imatinib Mesylate

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imatinib (Primary) ; Everolimus; Sirolimus
  • Indications Lymphangioleiomyomatosis
  • Focus Therapeutic Use
  • Acronyms LAMP-1
  • Most Recent Events

    • 20 May 2020 Primary endpoint has not been met. (Serum VEGF-D)
    • 20 May 2020 Results presented at the 116th International Conference of the American Thoracic Society
    • 09 Sep 2019 Status changed from active, no longer recruiting to completed.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top